Targeted Segments Leverage Sambria's rapid-onset trans-dermal anesthetic to address needs of dermatology, podiatry, pediatrics, and cosmetic/aesthetic practices seeking fast, deep analgesia. Focus outreach on clinics with in-office procedures where quick anesthesia improves throughput and patient comfort. Develop clinician education and sample kits to demonstrate outcomes.

Channel Expansion Actively recruit independent reps and distributors with established derm, podiatry and aesthetics networks to accelerate US reach. Provide comprehensive training, co-branded marketing materials, and pilot programs to prove value in real-world procedures. Leverage existing partnerships such as the MD Needle Pen collaboration to access practitioner bases and co-promote products.

Differentiated Value Position the trans-dermal permeation enhanced system as a faster, deeper-acting alternative to conventional topical anesthetics, enabling quicker onset and improved patient comfort during dermatology and aesthetic procedures. Emphasize compatibility with lidocaine, benzocaine and tetracaine formulations and potential time-savings for clinicians.

Partnership Potential Explore licensing or co-development partnerships with larger dermatology device manufacturers, cosmeceutical brands, and medical distributors to broaden distribution and accelerate market adoption. Consider bundled offerings that pair Sambria's topical anesthetics with related devices or procedural services in target specialties.

Growth Readiness Build a scalable sales enablement framework including a lightweight CRM, partner portal, clinical case studies, and ROI tracking. Invest in digital marketing and thought leadership to generate qualified leads in dermatology, podiatry, pediatrics and aesthetics, enabling faster partner onboarding and sales cadence.